StreetInsider.com News Articles

Form 4 Natera, Inc. For: Oct 21 Filed by: Sheena Jonathan

Fri, 23 Oct 2026 21:25:00 -0400

si-local-file:///var/storage/secattach/20261023/27228877.html

Roth/MKM Starts Natera (NTRA) at Buy

Fri, 23 Oct 2026 05:11:50 -0400

(Updated - October 23, 2026 5:11 AM EDT)

Roth/MKM analyst Max M initiates coverage on Natera (NASDAQ: NTRA) with a Buy rating and a price target of $475.00.

The analyst comments "We initiate coverage of Natera with a Buy rating and $475 price target. With an unmatched catalyst runway in oncology diagnostics, a high likelihood (in our view) that positive estimate revision trends continue, and a scaled financial profile that supports long-term profit potential and near-term investments to power the next decade of growth, NTRA remains a bellwether in growth diagnostics. We believe upward estimate revisions can support NTRA’s premium multiple over

Roth/MKM Starts Natera (NTRA) at Buy

Fri, 23 Oct 2026 05:11:50 -0400

(Updated - October 23, 2026 5:11 AM EDT)

Roth/MKM analyst Max M initiates coverage on Natera (NASDAQ: NTRA) with a Buy rating and a price target of $475.00.

Form 144 Natera, Inc. Filed by: Sheena Jonathan

Wed, 21 Oct 2026 13:09:00 -0400

http://archive.fast-edgar.com/20261021/ABZZN22CZ222ITZ2222D2ZZUDVMGZH2SBK82

Filed on: October 21, 2026

Form 4 Natera, Inc. For: Oct 16 Filed by: Sheena Jonathan

Tue, 20 Oct 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20261020/27211660.html

Natera (NTRA) PT Raised to $500 at Canaccord

Mon, 19 Oct 2026 07:51:13 -0400

Canaccord analyst Kyle Mikson raised the price target on Natera (NASDAQ: NTRA) to $500.00 (from $375.00) while maintaining a Buy rating.

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Sun, 18 Oct 2026 18:10:00 -0400

Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations

Signatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera’s ESMO program

AUSTIN, Texas--(BUSINESS WIRE)--

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.

New evidence highlights

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Sun, 18 Oct 2026 18:10:00 -0400

Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations

Signatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of 1 part per million, will be featured in Natera’s ESMO program

AUSTIN, Texas--(BUSINESS WIRE)--

New evidence highlights

Form 4 Natera, Inc. For: Oct 15 Filed by: Rabinowitz Matthew

Fri, 16 Oct 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20261016/27199061.html

Form 144 Natera, Inc. Filed by: Rabinowitz Matthew

Thu, 15 Oct 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20261015/27193628.html

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

Thu, 15 Oct 2026 12:46:00 -0400

Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care

Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of business and innovation

AUSTIN, Texas--(BUSINESS WIRE)--

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME’s Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.

TIME’s Best Inventions list, published annually, highlights the technologies and breakthroughs

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

Thu, 15 Oct 2026 12:46:00 -0400

Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care

Natera also named to Fortune’s Future 120, which highlights companies poised to define the next chapter of business and innovation

AUSTIN, Texas--(BUSINESS WIRE)--

TIME’s Best Inventions list, published annually, highlights the technologies and breakthroughs

Natera (NTRA) PT Raised to $480 at TD Cowen

Tue, 13 Oct 2026 09:32:19 -0400

TD Cowen analyst Dan Brennan raised the price target on Natera (NASDAQ: NTRA) to $480.00 (from $340.00) while maintaining a rating.

Natera (NTRA) PT Raised to $435 at Morgan Stanley

Tue, 13 Oct 2026 08:24:36 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Natera (NASDAQ: NTRA) to $435.00 (from $355.00) while maintaining a Overweight rating.

Natera and TransCode team up on colorectal cancer MRD trial

Tue, 13 Oct 2026 07:30:21 -0400

Natera, Inc. (Nasdaq: NTRA) and TransCode Therapeutics, Inc. (Nasdaq: RNAZ) have announced a collaboration to support patient enrollment in TransCode's Phase 2a clinical trial evaluating TTX-MC138 in colorectal cancer (CRC).

Under the agreement, Natera's Signatera test will be used to identify patients who have completed curative-intent therapy and test positive for molecular residual disease (MRD) with no radiographic evidence of disease. Those patients would be eligible for enrollment in the trial.

TTX-MC138 is designed to inhibit microRNA-10b (miR-10b), a biomarker linked to the emergence and progression of metastatic cancers, including CRC. TransCode describes the candidate as a first-in-class therapeutic targeting MRD-positive patients

Natera and TransCode team up on colorectal cancer MRD trial

Tue, 13 Oct 2026 07:30:21 -0400

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC).

The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-MC138 in patients with CRC. Patients will be eligible for enrollment if they have completed curative-intent therapy and

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tue, 13 Oct 2026 07:30:00 -0400

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment

Form 4 Natera, Inc. For: Oct 07 Filed by: Rabinowitz Matthew

Fri, 09 Oct 2026 21:25:00 -0400

si-local-file:///var/storage/secattach/20261009/27172583.html

FDA grants breakthrough device designation to Natera's cancer detection test

Fri, 09 Oct 2026 08:01:39 -0400

Natera, Inc. (NASDAQ: NTRA) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its multi-cancer early detection assay, a blood-based test designed to screen for multiple cancer types.

The designation applies to novel technologies intended to enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. The FDA evaluated data from 12 cancer types, examining the test's sensitivity, specificity, and cancer signal origin performance before granting the designation.

Natera's assay analyzes cell-free DNA in the blood to detect cancer signals. The Breakthrough Devices program is intended to speed up development, assessment, and regulatory review for

FDA grants breakthrough device designation to Natera's cancer detection test

Fri, 09 Oct 2026 08:01:39 -0400

Natera's assay analyzes cell-free DNA in the blood to detect cancer signals. The Breakthrough Devices program is intended to speed up development, assessment, and regulatory review for

FDA grants breakthrough device designation to Natera's cancer detection test

Fri, 09 Oct 2026 08:01:39 -0400

Natera's assay analyzes cell-free DNA in the blood to detect cancer signals. The Breakthrough Devices program is intended to speed up development, assessment, and regulatory review for

FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

Fri, 09 Oct 2026 08:00:00 -0400

Designation supports the development of a blood-based assay intended to screen for various cancers

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions.

Natera’s MCED assay analyzes cell-free DNA in the blood to screen for multiple cancers. In granting the BDD,